EPSOLAY
Peakbenzoyl peroxide
NDATOPICALCREAM
Approved
Apr 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
EPSOLAY (benzoyl peroxide) is 12. First approved in 2022.
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EPSOLAY is a topical benzoyl peroxide cream approved in April 2022 for treatment of acne vulgaris and other skin conditions. It functions as an oxidizing agent with bactericidal and keratolytic effects, though its precise mechanism in rosacea treatment remains unknown. The drug is absorbed by skin and converted to benzoic acid, which is eliminated renally.
$0.438MPart D
Peak15.0 years to LOEEarly-stage peak lifecycle with modest Medicare utilization (803 Part D claims in 2023) suggests a niche market position requiring focused brand development.
Mechanism of Action
12.1 Mechanism of Action Benzoyl peroxide is an oxidizing agent with bactericidal and keratolytic effects but the precise mechanism of action in the treatment of rosacea is unknown. 12.2 Pharmacodynamics The pharmacodynamics of EPSOLAY in the treatment of rosacea are unknown. 12.3 Pharmacokinetics…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris
Started Oct 2025
200 enrolled
Acne Vulgaris
"A Comparative Clinical Evaluation of the Efficacy of Topical Adapalene, Benzoyl Peroxide Gel, Oral Lactobacillus Rhamnosus, D-chiro-inositol, Inulin Capsule, and Their Fixed Combination in Mild to Moderate Acne Vulgaris Patients."
Started Feb 2022
59 enrolled
Acne Vulgaris
Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne
Started Feb 2017
50 enrolled
Acne Vulgaris
Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide
Started Jan 2017
22 enrolled
Actinic Keratosis
Adapalene 0.3% - Benzoyl Peroxide 2.5% Gel and Risk of Formation of Atrophic Acne Scars
Started May 2016
67 enrolled
Acne VulgarisAtrophic Acne Scars
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.